Dr. Devalle stared her scientific career in the field of Virology at FIOCRUZ, studying hepatitis virus and emergent viruses linked to hepatitis, but later migrated to the oncology and stem cell field, taking advantage of her molecular biology specialization.
She became a postdoctoral fellow at the New York branch of the Ludwig Institute for Cancer Research (LICR), where she studied CT-antigene gene’s function and conducted mapping of protein-protein interaction sites in melanoma. She also participated of studies on melanoma stem cell determination and driver mutations identification.
After returning to Brazil, she integrated the team of the National Embryonic Stem Cell Laboratory in partnership with the D’Or Institute, where she was offered a position as a quality control manager while also implementing molecular biology new procedures and technologies needed by the laboratory and collaborating with other members of the team in their thematic research.
Presently she is a member of the Paulo Niemeyer State Brain Institute’s research team, where she is establishing in vitro CRISPR-based models to study gene contribution to several cancers development as well as implementing ddPCR-based liquid biopsy for the follow-up of both brain and colon cancers’ patients. Additional interest include testing of novel compounds with anti-cancer activity and mechanisms of cancer resistance.
Dr. Devalle stared her scientific career in the field of Virology at FIOCRUZ, studying hepatitis virus and emergent viruses linked to hepatitis, but later migrated to the oncology and stem cell field, taking advantage of her molecular biology specialization.
She became a postdoctoral fellow at the New York branch of the Ludwig Institute for Cancer Research (LICR), where she studied CT-antigene gene’s function and conducted mapping of protein-protein interaction sites in melanoma. She also participated of studies on melanoma stem cell determination and driver mutations identification.
After returning to Brazil, she integrated the team of the National Embryonic Stem Cell Laboratory in partnership with the D’Or Institute, where she was offered a position as a quality control manager while also implementing molecular biology new procedures and technologies needed by the laboratory and collaborating with other members of the team in their thematic research.
Presently she is a member of the Paulo Niemeyer State Brain Institute’s research team, where she is establishing in vitro CRISPR-based models to study gene contribution to several cancers development as well as implementing ddPCR-based liquid biopsy for the follow-up of both brain and colon cancers’ patients. Additional interest include testing of novel compounds with anti-cancer activity and mechanisms of cancer resistance.